HCC
Survey Uncovers Barriers To HCC Surveillance
In the surveillance of patients with known risk factors for hepatocellular carcinoma, numerous obstacles exist on ...
JULY 8, 2022
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb (BMS) has voluntarily withdrawn from the U.S. market the ...
JULY 27, 2021
For Cirrhotics With HCV, Monitoring for Liver Cancer Warranted Even After Viral Eradication
Although recent advances in direct-acting antiviral therapy have made sustained virologic response (SVR) a reality ...
MARCH 5, 2021
Hep C Cure Linked to Lower Mortality From Liver Cancer
Curing he hepatitis C infection appears to dramatically improve five-year survival rates in people with liver ...
MARCH 17, 2020
Nivolumab-Ipilimumab Combo Approved to Treat Previously Treated HCC
The FDA granted accelerated approval for the use of nivolumab plus ipilimumab to treat hepatocellular carcinoma in ...
MARCH 12, 2020
Report From HOPA 2019: Second-Line Treatment of Advanced HCC
Many clinicians continue to debate the best second-line agent for HCC from a multitude of options. Julianne Orr, ...
APRIL 5, 2019
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
Keytruda Granted Accelerated Approval for Treatment of HCC
The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor ...
NOVEMBER 16, 2018
Large Study Confirms DAAs Protect Against HCC When SVR Achieved
Patients with HCV who are successfully treated with direct-acting antiviral agents experience a dramatic reduction ...
APRIL 4, 2018
Aspirin Lowers HCC Risk in Hep B Patients
Daily aspirin is significantly associated with a reduced risk for liver cancer in patients with hepatitis B virus, ...
APRIL 4, 2018
